🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

As Dr. Imane El Dika rightly points out, early molecular testing is critical in 1L BTC, a target-rich disease where standard approaches are failing to move the needle. #GI23

#GI23 👇🏾A tumor type to not forgot about #BRCA #DDR 🧬aberrations is #cholangiocarcinoma. Cholangiocarcinoma Foundation Anywhere from 4-10% depending on race and regional variations. OncoAlert

Excellent overview by Jeanne Tie on the role of ctDNA in adjuvant #CRCSM - ctDNA appears poised to transform existing stage/risk factor stratification, but many answers are still forthcoming. #GI23

Inspiring @asco #GI23 keynote by Lorna H. McNeill PhD from @mdandersonnews highlighting the importance of focusing upstream to mitigate health disparities in cancer and how community engagement can help us to mitigate health disparities in cancer and cancer trials.

The SUNLIGHT trial of Lonsurf +/- bev in refractory mCRC, presented by Josep Tabernero, met its primary endpoint with improved OS by 3.3 months and improvement in QOL endoints as well. A new SOC #GI23

Discovery of Multiple Myeloma Targets using #SingleCell #proteomics data from John F. DiPersio Lab, Ding lab, and ravi vij! Out now in Cancer Research aacrjournals.org/cancerres/arti…

📅 February 16 is World Cholangiocarcinoma Day! 👉sign the CCA pledge to show your commitment to raising awareness and increasing education of CCA: bit.ly/3HvXtcP ESMO - Eur. Oncology OncoAlert EASL Education #livertwitter ENS-CCA

A11: Navicixizumab phase I in #CRCSM #CRCTrialsChat

#ASCO2023 thank you so much for inviting me to be a speaker on Treatment sequencing of #neuroendocrinetumors Rodrigo Taboada ascopubs.org/doi/abs/10.120… BI BOB Neuroendocrine Cancer

Please come and visit our posters Siteman Cancer Center Michael Iglesia, MD, PhD #ASCO2023

Are you an oncology trainee interested in drug development? Apply by July 26 for the October 2023 U.S. FDA - ASCO Fellows' Day Workshop! Learn about the FDA, clinical trial design, & oncology drug/device approval process, in person or online. asco.smapply.org/prog/OctoberFe… #MedEd

The ICTS announces the 2023 Scholars for PROUD-MED, the Program for Underrepresented in Medicine for Equity and Diversity. PROUD-MED, a new initiative to enhance underrepresented in medicine (URiM) faculty development. Test Account @WUDeptMedicine #WUICTS l8r.it/Jfjk

Siteman researchers receive $10.9 million NCI SPORE grant for pancreatic cancer David DeNardo WUSM Katrina Pedersen, MD, MS WashU Medicine Department of Surgery @WashUOnc @WUDeptMedicine Siteman Cancer Center #PancreaticCancer #WashUMed source.wustl.edu/2023/10/pancre…

Our new manuscript is out today in npj Journals Precision Oncology on tumor microenvironment (TME) composition in pancreatic cancer (PDAC)! nature.com/articles/s4169… Abul Usmani Prathamesh Chati Aadel Chaudhuri, MD PhD. Tweetorial below …

Excited to share that our most recent pan-cancer study is out in nature! We uncovered cis- and trans- epigenetic events linked to cancer initiation and progression across 11 cancer types. #PanCancer #HTAN #Epigenetics nature.com/articles/s4158…

In contrast to the observations seen with NTRK fusion, NTRK VUS’s are associated with better response to immune checkpoint inhibitors. Additional work to understand why is ongoing. #SITC2023 Thank you Michael Iglesia, MD, PhD and co-authors

[EO kaj poste EN] Jam estas tiu tago - #ZamenhofaTago 2023! Hodiaŭ geesperantistoj ĉirkaŭ la tuta mondo samtempe festos sian komunan literaturon, kulturon, kaj certe, lingvon. Ni esperas, ke vi ĉiuj partoprenos kaj mirindajn kaj lernadoplenajn renkontiĝojn!

Today is #WorldCCADay! We stand with Global Cholangiocarcinoma Alliance in calling for a smoother journey to diagnosis for patients with #cholangiocarcinoma. It’s time to #BeClearOnCCA. Sign the pledge to show your support: globalccaalliance.com/sign-the-pledge. 💚

Another Human Tumor Atlas Network article Nature Cancer OUT NOW! 'Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages' ✏️By Li Ding and colleagues nature.com/articles/s4301…